TargetBeta
PDGFRB
platelet derived growth factor receptor beta · also JTK12, CD140b, PDGFR1, PDGFR · CD molecules
7 programs in company-led studies act on PDGFRB, from 7 companies: 4 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 404 running | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, RAF1, RET, TEK | ChEMBL |
| imatinibrule | Novartis | phase 4 | 703 running | ABL1, BCR, KIT | ChEMBL |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 761 running | FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA | ChEMBL |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 407 running | FLT4, KDR, KIT | ChEMBL |
| quizartinibrule | Daiichi Sankyo | phase 3 | 225 running | CSF1R, FLT3, KIT, PDGFRA, RET | ChEMBL |
| masitinibrule | AB Science | phase 3 | 384 running | FGFR3, KIT, PDGFRA | ChEMBL |
| seralutinibrule | GB002, Inc., a wholly owned subsidiary of Gossamer Bio | phase 3 | 82 running | CSF1R, KIT, PDGFRA | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Neoplasms, 3 programs
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Pulmonary Arterial Hypertension, 2 programs
- Alzheimer Disease, 1 program
- Amyotrophic Lateral Sclerosis, 1 program
- Arthritis, Rheumatoid, 1 program
- Asthma, 1 program
- Carcinoma, Hepatocellular, 1 program
- Colorectal Neoplasms, 1 program
- Endometrial Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026seralutinib · GB002, Inc., a wholly owned subsidiary of Gossamer Bio · phase 3 · NCT06274801
- Mar 31, 2027anlotinib · Sino Biopharmaceutical · phase 3 · NCT07438886
- May 1, 2027quizartinib · Daiichi Sankyo · phase 3 · NCT03793478
- Sep 30, 2027regorafenib · Bayer · phase 4 · NCT02955940
- Oct 2027imatinib · Novartis · phase 4 · NCT07406633
- Dec 2027masitinib · AB Science · phase 3 · NCT03127267
- Nov 14, 2028nintedanib · Boehringer Ingelheim · phase 4 · NCT07335562
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.